AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

CAPS Rating: 3 out of 5

Results 1 - 9 of 9

Recs

0
Member Avatar VicthebrickV (53.91) Submitted: 9/26/2014 4:22:06 PM : Underperform Start Price: $5.45 ACRX Score: -20.77

Did not get drug approval

Recs

0
Member Avatar oscillation (< 20) Submitted: 7/28/2014 10:55:58 PM : Outperform Start Price: $6.22 ACRX Score: +6.15


AcelRx stock plunges after FDA rejects pain drug device
Reuters
13 hours ago

July 28 (Reuters) - Shares of AcelRx Pharmaceuticals Inc plunged nearly 28 percent in premarket trading, after the U.S. Food and Drug Administration rejected its pain drug device, Zalviso, late on Friday.

Analysts said they expected the product to eventually receive approval as the issues cited in Zalviso's "rather mild" complete response letter were requests for additional information largely around the device.

AcelRx said it would resubmit its marketing application for Zalviso by the end of the year, pending further discussions with the FDA.

The needle-free, handheld, patient-controlled system is designed for the management of moderate-to-severe pain in adult patients in a hospital setting.

Zalviso, consists of sufentanil, an opioid, and is delivered using AcelRx's flagship NanoTab technology which enables rapid absorption when placed under the tongue.

In its complete response letter to the company, the agency did not ask for any additional efficacy trials but requested additional information to ensure proper use of the device.

Canaccord Genuity analyst John Newman cut his rating on the stock to "hold" from "buy" and halved his price target to $8 based on "on the unexpected magnitude of delay for Zalviso and concerns over stability/shelf life" of the product.

Roth Capital Partners, Mizuho and JMP Securities analysts said the rejection would likely result in a one-year delay to approval as the FDA's requests were readily addressable.

The FDA sought changes to the instructions for use for the device and additional data to support its shelf life.

"ACRX was surprised to receive a CRL for issues it believes could have been resolved with a routine (review) PDUFA delay; almost exclusively straightforward device/instruction issues rather than drug concerns," JMP analyst Oren Livnat said.

"This increases our overall confidence in approvability, albeit after an unfortunate delay," Livnat said, maintaining his "market outperform" rating on the stock.

The delay bodes well for the The Medicines Company whose rival experimental pain product Ionsys will now likely gain a timing advantage. The company submitted an application to market the treatment in late June.

"Thus, assuming a first-pass approval, Ionsys now appears to have at least a 2-month head start on Zalviso," Roth Capital Partners analyst Ed Arce said, cutting his price target on the stock to $16 from $22.

RBC Capital Markets analysts reduced their 2021 U.S. sales forecast for Zalviso by $50 million to $350 million.

An application to market Zalviso in Europe was submitted by the company's German partner Grunenthal Group earlier in July.

The product is also undergoing development for use in breakthrough pain in cancer patients, pain relief for patients undergoing procedures in a physician's office and acute pain.

Four brokerages - Roth Capital Partners, JMP Securities, Mizuho and RBC Capital - kept their positive ratings on the stock.

The Redwood City, California-based specialty pharmaceutical company's stock was trading at $7.77 premarket on Monday after closing at $10.83 on the Nasdaq on Friday.

(Reporting by Natalie Grover in Bangalore; Editing by Saumyadeb Chakrabarty)

Recs

0
Member Avatar Investinguppy (< 20) Submitted: 6/17/2014 11:01:54 PM : Outperform Start Price: $10.70 ACRX Score: -42.09

Trading opportunity leading up to PDUFA

Recs

0
Member Avatar TerryFool (43.30) Submitted: 3/3/2014 11:54:36 AM : Outperform Start Price: $9.77 ACRX Score: -43.25

ACRX BP 10 TP 15 1YR REV 100%

Recs

0
Member Avatar cavemantrader (87.32) Submitted: 12/16/2013 1:21:07 PM : Outperform Start Price: $9.86 ACRX Score: -45.91

Added to the NASDAQ Biotechnology Index, ACRX and Grunenthal GmbH announced they have entered into a commercial collaboration for ARX-01 in the EU. Undervalued, revenues picking up, and a state of art product with the potential of blockbuster revenue. Strong buy here, on a risk/reward basis.

Recs

0
Member Avatar TerryHoodSr (59.57) Submitted: 8/25/2013 2:11:51 PM : Outperform Start Price: $6.97 ACRX Score: -18.44

spec TP $14

Recs

0
Member Avatar tregister6 (< 20) Submitted: 6/18/2013 8:44:13 PM : Outperform Start Price: $9.65 ACRX Score: -53.88

their pipeline has huge potential with a replacement for PCAs that doesn't require an IV. Also their product that is earliest in development is backed by the US Army that is intended to be used in the field.

Recs

0
Member Avatar SUPERSTOCKS007 (< 20) Submitted: 5/27/2013 1:47:10 PM : Outperform Start Price: $8.10 ACRX Score: -39.12

corrects inferior product in use

Recs

3
Member Avatar zzlangerhans (99.85) Submitted: 9/15/2012 1:06:39 AM : Outperform Start Price: $3.51 ACRX Score: +55.87

I wish I could have gotten my green thumb in on AcelRx when I actually bought 3000 shares at 2.95 for the GBMB on August 22, but Motley Fool was protecting you from learning about interesting stocks that don't meet an arbitrary threshold of share price x median three month volume. I guess anyone who wants the full story can follow me on Twitter.

AcelRx is developing sublingual opiate tablets for various pain indications. Three phase III trials of ARX-01 sublingual sufentanil NanoTabs as post-operative PCA are currently in progress, with topline data from two of those trials expected in Q4 2012. You might have read my criticisms of pain drug developers before, as they have a horrible long-term track record as investments, but shhhhhh. When word gets out about a phase III catalyst in the short-term, pumpers come out from under their rocks and reason and logic go out the window.

AcelRx has mostly operated under the radar, with low trading volumes since the IPO in February 2011 and a market cap under 100M. The share price cracked 4.5 in mid 2011 but dropped under 2 at the end of 2011 before the early 2012 small cap bull market took over. I think I got in at a good price, but the stock is a little harder to recommend at this level. I'm opening the green thumb now to document the trade and also because I think there's a potential to go over 4 before the phase III data. This isn't a bad bet for positive data since one phase III trial compares ARX-01 to placebo and the other has an endpoint of non-inferiority to morphine PCA. However, I was burnt on a similar assumption with BioDelivery Sciences last year and so hopefully I'll be out of the trade before the catalyst.

Long-term , I think AcelRx has fairly lousy prospects based on the empiric performance of pain stocks and my intuition that cheap generics are doing an adequate job for PCA.

Results 1 - 9 of 9

Featured Broker Partners


Advertisement